Literature DB >> 28671042

Progress in the treatment of advanced gastric cancer.

Zheyu Song1, Yuanyu Wu1, Jiebing Yang2, Dingquan Yang1, Xuedong Fang1.   

Abstract

Gastric cancer is one of the most common malignant tumors in the digestive system. Surgery is currently considered to be the only radical treatment. As surgical techniques improve and progress is made in traditional radiotherapy, chemotherapy, and the implementation of neoadjuvant therapy, the 5-year survival rate of early gastric cancer can reach >95%. However, the low rate of early diagnosis means that most patients have advanced-stage disease at diagnosis and so the best surgical window is missed. Therefore, the main treatment for advanced gastric cancer is the combination of neoadjuvant chemoradiotherapy, molecular-targeted therapy, and immunotherapy. In this article, we summarize several common methods used to treat advanced gastric cancer and discuss the progress made in the treatment of gastric cancer in detail. Only clinical practice and clinical research will allow us to prolong the survival time of patients and allow the patients to truly benefit by paying attention to the individual patient characteristics, drug choice, and developing a reasonable and comprehensive treatment plan.

Entities:  

Keywords:  Advanced gastric cancer; immunotherapy; molecular-targeted therapies radiotherapy; neoadjuvant chemotherapy

Mesh:

Year:  2017        PMID: 28671042     DOI: 10.1177/1010428317714626

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  281 in total

1.  Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.

Authors:  Mateusz J Swierz; Dawid Storman; Robert P Riemsma; Robert Wolff; Jerzy W Mitus; Michal Pedziwiatr; Jos Kleijnen; Malgorzata M Bala
Journal:  Cochrane Database Syst Rev       Date:  2020-03-12

Review 2.  Promising clinical application of ctDNA in evaluating immunotherapy efficacy.

Authors:  Li Li; Jun Zhang; Xiaoyue Jiang; Qin Li
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

3.  Engulfment and cell motility 1 promotes tumor progression via the modulation of tumor cell survival in gastric cancer.

Authors:  Young-Lan Park; Jung-Ho Choi; Sun-Young Park; Hyung-Hoon Oh; Dong-Ho Kim; Yoon-Jin Seo; Jae-Kyoung So; Kaeun Song; Min-Seok Cho; Min-Woo Chung; Ji-Yun Hong; Ki-Hyun Kim; Eun Myung; Dae-Seong Myung; Sung-Bum Cho; Wan-Sik Lee; Daeho Park; Young-Eun Joo
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

4.  Ghrelin Affects Gastric Cancer Progression by Activating AMPK Signaling Pathway.

Authors:  Xiao-Lin Hu; Yong-Jun Zhu; Chang-Hua Hu; Li You; Juan Wu; Xiao-Yan He; Wen-Jie Huang; Zong-Hui Wu
Journal:  Biochem Genet       Date:  2021-01-13       Impact factor: 1.890

5.  MicroRNA-598 inhibits the growth and maintenance of gastric cancer stem-like cells by down-regulating RRS1.

Authors:  Yanling Ma; Fei Yan; Wujie Wei; Jie Deng; Li Li; Li Liu; Jianhai Sun
Journal:  Cell Cycle       Date:  2019-08-23       Impact factor: 4.534

6.  Significance and prognostic role of human epidermal growth factor receptor 2 and RAB1A expression in gastric cancer.

Authors:  Bihong Xu; Chunyu Huang; Xianzi Yang; Xiangzhao Li; Liang Li; Yanqing Ding
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

7.  Expression and clinical significance of miR-338 and miR-20a in serum of patients with gastric carcinoma.

Authors:  Min Li; Jueping Feng; Chang Gao; Wen Sun; Yilian Chen
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

8.  CircRNA Hsa_circ_0001017 Inhibited Gastric Cancer Progression via Acting as a Sponge of miR-197.

Authors:  Hui Li; ChangPing Shan; JunYe Wang; ChengJiu Hu
Journal:  Dig Dis Sci       Date:  2020-08-01       Impact factor: 3.199

9.  Contribution of chemotherapy to improved prognosis in stage 4 gastric cancer: trend analysis of a regional population-based cancer registry in Japan.

Authors:  Tomomi Nakao; Rena Kaneko; Hirokazu Tanaka; Shunsuke Kobayashi; Risa Omori; Yuichiro Yano; Kentaro Kamada; Takashi Ikehara; Yuzuru Sato; Yoshinori Igarashi
Journal:  Int J Clin Oncol       Date:  2020-11-05       Impact factor: 3.402

10.  Lidocaine alleviates cisplatin resistance and inhibits migration of MGC-803/DDP cells through decreasing miR-10b.

Authors:  Xiaomin Zhang; Guangfeng Gu; Xuanfei Li; Chaopei Zhang
Journal:  Cell Cycle       Date:  2020-09-05       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.